BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2020

View Archived Issues

Buyer beware for SARS-CoV-2 antibody detection

Read More

Breathing new life into obsolete antibiotics

Read More

Sorrento reports preclinical data on COVI-GUARD and COVI-AMG for COVID-19

Read More

Heparan sulfate acts as a coreceptor of SARS-CoV-2, priming the spike protein for ACE2 interaction

Read More

Bifunctional hybrid nanoscaffold for SCI: anti-inflammation and biomimetic neural matrix formation

Read More

Interim data from phase I/IIa study of Janssen's COVID-19 vaccine candidate

Read More

Moleculin discovers new antimetabolites with significant in vitro activity against COVID-19

Read More

FDA accepts IND application for lucinactant in COVID-19-associated acute lung injury

Read More

Positive topline phase I data for ROSgard in patients with renal impairment

Read More

Lipid metabolism controls lung cancer metastasis, not just diseases like atherosclerosis

Read More

Biogen identifies new N-acetyl-beta-D-glucosaminidase inhibitors

Read More

Janssen presents anti-hepatitis B virus compounds

Read More

ER Stress Research Institute patents eIF-2-alpha inhibitors

Read More

Universidade Nova de Lisboa and collaborators describe new free radical scavengers/antioxidants

Read More

Pembrolizumab in first-line esophageal cancer: first data from KEYNOTE-590

Read More

New IL-7 modulators discovered at Leo Pharma

Read More

AK-104 demonstrates safety and antitumor activity in patients with mesothelioma

Read More

Sarepta reports data from ongoing first-in-human study of SRP-9003 for LGMD2E

Read More

Oncternal Therapeutics presents phase I data for TK-216

Read More

REG-1-alpha identified as a marker of gestational diabetes

Read More

FDA approves Xeljanz for active polyarticular course juvenile idiopathic arthritis

Read More

Ironwood to discontinue IW-3718 for GERD

Read More

Zucara initiates phase I study of ZT-01 to prevent insulin-induced hypoglycemia in type 1 diabetes

Read More

FDA accepts IND for phase IIb study of AR-15512 in dry eye disease

Read More

New phase III trial to evaluate bucillamine in COVID-19

Read More

Arcutis reports topline phase II data on roflumilast topical foam for seborrheic dermatitis

Read More

Regeneron reports data on REGN-COV2 in nonhospitalized patients with COVID-19

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing